Traders should view this as a major win for Teva's patent enforcement strategy; potential for positive stock reaction and increased valuation of its migraine franchise. Monitor for subsequent damages calculations or settlement discussions with Lilly.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $31.26entry
- T+1 · 7mo ago +3.62%α +2.40% · $32.39
- T+5 · 7mo ago −0.19%α −1.18% · $31.20
- T+20 · 6mo ago +15.98%α +10.16% · $36.25
- T+60 · 4mo ago +5.42%α −2.18% · $32.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment invalidating Teva's headache-related patents, reinstating a jury verdict that Eli Lilly willfully infringed the patents. This strengthens Teva's IP position and may lead to damages or licensing revenue.
Court Ruling Details
Key Facts
- Federal Circuit reversed lower court's invalidation of Teva's U.S. Patent Nos. 8,586,045, 9,884,907, and 9,884,908
- Appellate court reinstated jury finding that Eli Lilly willfully infringed the patents
- Ruling affirms validity of Teva's patents covering use of humanized anti-CGRP antagonist antibodies to treat headache
- Case remanded for further proceedings consistent with the opinion
- Costs awarded to Teva
Financial Impact
Potential for significant damages award and/or future royalty income from Lilly's Emgality product, which generated $1.8B in 2025
Risk Factors
- Lilly may appeal to Supreme Court
- Lower court may still limit damages on remand
- Potential for future challenges to patent scope
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2pxskqsa-TEVA |
Track record
61 reports on TEVA
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers